CD274 and non-small cell lung carcinoma: This indicates that the combination of anti-PD-1/PD-L1 antibodies with cytotoxic chemotherapies and/or anti-CTLA-4 antibodies is unable to fully restore the dysfunctional state of T cells or NK cells in NSCLC with these mutations.